» Articles » PMID: 24338934

Vitamin D Status of Human Immunodeficiency Virus-positive Patients with Advanced Liver Disease Enrolled in the Solid Organ Transplantation in HIV: Multi-site Study

Overview
Journal Liver Transpl
Date 2013 Dec 17
PMID 24338934
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

An optimal vitamin D status may benefit liver transplantation (LT) patients. Higher levels of 25-hydroxyvitamin D [25(OH)D] mitigate steroid-induced bone loss after LT, correlate with better hepatitis C virus treatment responses, and increase graft survival. This study investigated 25(OH)D levels and assessed strategies for vitamin D deficiency prevention in human immunodeficiency virus (HIV)-positive patients with advanced liver disease who were enrolled in the Solid Organ Transplantation in HIV: Multi-Site Study. 25(OH)D was measured in banked specimens from 154 LT candidates/recipients with the DiaSorin assay; deficiency was defined as a 25(OH)D level < 20 ng/mL. Information about vitamin D supplement use after LT was obtained from medication logs and via surveys. Logistic regression, Cox regression, and linear repeated measures analyses were performed with SAS software. We found that none of the 17 academic medical centers in the United States routinely recommended vitamin D supplements before LT, and only a minority (4/17) recommended vitamin D supplements to all patients after LT. Seventy-one percent of the 139 patients with pre-LT values had vitamin D deficiency, which was significantly associated with cirrhosis (P = 0.01) but no other variable. The vitamin D status improved modestly after LT; however, the status was deficient for 40% of the patients 1 year after LT. In a multivariate linear repeated measures model, a higher pre-LT 25(OH)D level (P < 0.001), specimen collection in the summer (P < 0.001), a routine vitamin D supplementation strategy after LT (P < 0.001), and the time elapsing since LT (P = 0.01) were significantly associated with increases in the post-LT 25(OH)D level; black race was associated with a decreased level (P = 0.02). In conclusion, the majority of patients awaiting LT were vitamin D deficient, and approximately half were vitamin D deficient after LT. More extensive use of vitamin D supplements, more sun exposure, or both are needed to prevent this deficiency in HIV-positive LT candidates and recipients.

Citing Articles

A Prospective Open-Label Dose-Response Study to Correct Vitamin D Deficiency in Cirrhosis.

Bowman C, Bichoupan K, Posner S, Schonfeld E, Pappas A, Woodward M Dig Dis Sci. 2024; 69(3):1015-1024.

PMID: 38217683 DOI: 10.1007/s10620-023-08224-5.


Nutritional and Lifestyle Therapy for NAFLD in People with HIV.

Cinque F, Cespiati A, Lombardi R, Guaraldi G, Sebastiani G Nutrients. 2023; 15(8).

PMID: 37111209 PMC: 10140991. DOI: 10.3390/nu15081990.

References
1.
Cozzolino M, Vidal M, Arcidiacono M, Tebas P, Yarasheski K, Dusso A . HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS. 2003; 17(4):513-20. DOI: 10.1097/00002030-200303070-00006. View

2.
Bikle D . Vitamin D and bone. Curr Osteoporos Rep. 2012; 10(2):151-9. PMC: 3688475. DOI: 10.1007/s11914-012-0098-z. View

3.
Petta S, Ferraro D, Camma C, Cabibi D, Di Cristina A, Di Marco V . Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C. Antivir Ther. 2012; 17(5):823-31. DOI: 10.3851/IMP2100. View

4.
Falleti E, Bitetto D, Fabris C, Fattovich G, Cussigh A, Cmet S . Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C. Hepatology. 2012; 56(5):1641-50. DOI: 10.1002/hep.25848. View

5.
Pourgholami M, Akhter J, Lu Y, Morris D . In vitro and in vivo inhibition of liver cancer cells by 1,25-dihydroxyvitamin D3. Cancer Lett. 2000; 151(1):97-102. DOI: 10.1016/s0304-3835(99)00416-4. View